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Abstract 
In order to interpret bone turnover markers (BTMs), we need to establish healthy reference 
intervals. It is difficult to establish reference intervals for older women because they commonly 
suffer from diseases or take medications that affect bone turnover. The aims of this study were: (1) 
to identify diseases and drugs that have a substantial effect on BTMs; (2) to establish reference 
intervals for premenopausal and postmenopausal women; and (3) to examine the effects of other 
factors on BTMs in healthy postmenopausal women. We studied women aged 30 W39 years (n = 258) 
and women aged 55 W79 years (n = 2419) from a five-European centre population-based study. We 
obtained a nonfasting serum and second morning void urine samples at a single baseline visit. BTMs 
were measured using automated immunoassay analysers. BTMs were higher in patients with vitamin 
D deficiency and chronic kidney disease. Three or more BTMs were higher in women who were 
osteoporotic and at least two BTMs were lower in women who were oestrogen replete, taking 
osteoporosis treatments or having diseases known to affect bone turnover. These were used as 
exclusion criteria for selecting the populations for the reference intervals. The reference intervals for 
BTMs were higher in postmenopausal than premenopausal women. Levels of BTMs were not 
dependent on geographical location and increased with age. 
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Introduction 
Bone remodelling can be assessed easily and non-invasively by the measurement of serum and 
urinary biochemical bone turnover markers (BTMs). The bone resorption markers include C-terminal 
crosslinking telopeptides of type I collagen (CTX) and N-terminal crosslinking telopeptides of type I 
collagen (NTX). The bone formation markers include procollagen type I N-propeptide (PINP), bone 
alkaline phosphatase (bone ALP) and osteocalcin (OC) [1]. BTMs provide a dynamic assessment 
about the pathophysiology of metabolic bone disease, treatment monitoring and provide additional 
information to bone mineral density assessment measured by dual-energy X-ray absorptiometry 
(DXA). BTMs are increased in metabolic bone diseases such as osteoporosis where there is 
accelerated bone loss [2]. In some studies, high BTMs are associated with major osteoporotic 
fractures; for example, CTX was predictive of hip fracture in the EPIDOS cohort when patients were 
not fasting and samples were collected during the afternoon [3] and with bone loss [4,5]. 
 
Several BTM reference intervals for healthy premenopausal women have previously been 
established [6 W9]. It has been proposed that the purpose of these is to monitor the response of 
osteoporotic patients to treatments. The proposed goal of antiresorptive treatments is to reduce 
BTMs to the lower part of the healthy premenopausal reference interval [10]. It is therefore 
essential to have a valid and robust reference interval.  
 
BTM reference intervals for healthy postmenopausal women would also be useful. They may help 
clinicians to identify patients who may have secondary osteoporosis. However, they are difficult to 
establish because older women commonly suffer from disease or take medications that are known 
to affect bone metabolism, and therefore there are limited data [11].  It has been demonstrated that 
severe vitamin D deficiency as defined by 25 hydroxy vitamin D (25(OH)D) serum levels <12.5 nmol/L 
causes osteomalacia in adults [12 W14]. This is associated with hypocalcaemia, impaired 
mineralisation of bone, accelerated bone loss, lower bone mineral density (BMD) and increased 
bone turnover [15]. Vitamin D insufficiency as defined by 25(OH)D levels between 30 and 50 nmol/L 
is associated with an increase in parathyroid hormone (PTH) levels that is attributed to decreased 
calcium absorption. This may indicate secondary hyperparathyroidism in postmenopausal women 
[16, 17]. 
 
Chronic kidney disease (CKD) is also associated with impaired bone remodelling causing disorders 
such as osteitis fibrosa characterised by high bone turnover. Previous studies have reported elevated 
BTMs in patients with kidney impairment [18 W20]. Postmenopausal women with osteoporosis are 
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treated with antiresorptive therapies that have a significant effect on bone remodelling. The 
reduction in BTMs are associated with increased bone mass and fracture risk reduction. For 
example, a 3-year trial of risedronate demonstrated a significant association between reduction in 
vertebral fracture risk and decreased levels of bone resorption markers and increased BMD [10]. The 
relationships between decreased bone ALP and P1NP and vertebral fracture risk were demonstrated 
with alendronate and zoledronic acid, respectively [21, 22]. These data have been supported by 
other studies [21, 22]. 
 
The usual approach to establish reference intervals is to define exclusion criteria. We have 
taken a different approach; we have measured BTMs in the whole population and examined 
whether the exclusion criteria are valid. 
 
Comparisons between BTM reference intervals for healthy postmenopausal and premenopausal 
women can also be performed. The aims of this work were: (1) to identify diseases and drugs that 
have a substantial effect on BTMs so that they can be used as exclusion criteria; (2) to establish 
reference intervals for premenopausal and postmenopausal women in a nonfasting state and 
determine whether they are different; and (3) to examine the effects of lifestyle and geographical 
differences on BTMs in healthy postmenopausal women. 
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Materials and Methods 
Study design and patients 
The design of the Osteoporosis and Ultrasound (OPUS) study has previously been reported [23] and 
is summarised briefly here. OPUS was a five-European centre population-based study: Sheffield, 
Aberdeen, Berlin, Kiel and Paris. The study was ĐŽŽƌĚŝŶĂƚĞĚďǇƚŚĞ ‘DĞĚŝǌŝŶŝƐĐŚĞWŚǇƐŝŬ ?ŝŶ<ŝĞů ?ůů
investigations were conducted in accordance with the Declaration of Helsinki and ethical approval 
was obtained from the local ethics committees and written informed consent was obtained from 
each subject. 
 
For this work we studied 2419 older women aged 55 W80 years and 258 younger women aged 30 W39 
years from the OPUS study population. A modified version of the European Vertebral Osteoporosis 
Study (EVOS) risk factor questionnaire [24] was administered to each subject. From this we were 
able to collect medical and lifestyle information. Medical history of diseases and treatments was 
recorded and subjects were classified as smokers if they were current smokers and alcohol intake 
was recorded as number of drinks per week. BMD was measured at the spine and total hip using 
DXA. Nonfasting venous blood samples were collected from each subject between 12:00 and 15:00 
into serum-separating tubes. The blood was left to clot for 30 min at room temperature and 
centrifuged at 2500 g for 10 min. The serum was then collected and stored at -80 °C until analysis. 
Second morning void urine samples were collected and stored at -20 °C until analysis. 
 
Biochemical measurements 
The following biochemical tests were measured in the Bone Biochemistry Laboratory, Sheffield, UK, 
using automated ƐǇƐƚĞŵƐĂĐĐŽƌĚŝŶŐƚŽƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ protocol. 
 
CTX, intact PINP, bone ALP and 25(OH)D were measured in serum using the IDS-iSYS automated 
immunoassays (Immunodiagnostic Systems, Boldon, UK). The inter assay coefficients of variation 
(CVs) were 6.5%, 7.2%, 3.5% and 6.7%, respectively. N-Mid osteocalcin was measured in serum using 
the Elecsys 2010 automated immunoassay (Roche Diagnostics, Penzberg, Germany). The inter assay 
CV was 6.3%. NTX was measured using the Ortho Clinical Diagnostics automated immunoassay (High 
Wycombe, UK). The inter assay CV was 6.4%. NTX was expressed as a ratio to creatinine and the 
inter assay CV for creatinine was 1.8%. 
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Serum creatinine was measured using the cobas c 311 automated analyser (Roche Diagnostics). This 
was used to calculate the estimated glomerular filtration rate (eGFR) using the formula based on the 
Modification of Diet and Renal Disease (MDRD) [25]. 
 
Medical conditions and treatments 
We defined several diseases and treatments that may have an effect on bone remodelling. These 
were: (1) vitamin D deficiency if 25(OH)D was <30 nmol/L; (2) renal impairment if eGFR was 
< 30 mL/minute/1.73m² (CKD stages 4 and 5) as categorised by KDIGO (Kidney Disease: Improving 
Global Outcomes) [26, 27]; (3) osteoporosis at the spine or total hip if the BMD T-score ǁĂƐA?2.5; (4) 
other adverse conditions identified in the questionnaire: inflammatory bowel disease, rheumatoid 
arthritis, bone diseases other than osteoporosis, gastric surgery, hyperthyroidism, diabetes, liver 
ĚŝƐĞĂƐĞ ?ŐůƵĐŽĐŽƌƚŝĐŽŝĚƐ ?A?7.5mg prednisolone equivalent, A? ?ŵŽŶƚŚƐ ?ŽƌĂůĐŽŚŽůintake >14 units 
per week; and (5) oestrogen replete, that is, still premenopausal, or current/recent antiresorptive 
treatments. 
 
Statistical analyses 
The data for CTX, NTX, bone ALP and osteocalcin had a skewed distribution and were therefore log10 
transformed to achieve normality. Multiple linear regression coefficients were used to determine 
the association between BTMs and diseases and treatments, adjusting for age and menopause 
status. Subjects were categorised by the absence (0) or presence (1) of disease or treatment. The 
coefficients were the percentage difference in the geometric mean of the BTM associated with the 
presence of disease. 
 
A 95% reference interval was calculated for each BTM as a mean ±1.96 s.d. The confidence intervals 
(CIs) for the upper and lower bounds of the reference interval were calculated as boundary ±1.96 
s.e. where: 
 
Ǥ Ǥ ൌ  ඨǤ Ǥଶ ൅  ?Ǥ ? ?ଶǤ Ǥଶ ?ሺ െ  ?ሻ  
 
Where s.d. is standard deviation, s.e. is standard error of the estimate of the boundaries and N is the 
number of subjects. 
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PINP was not normally distributed after log10 transformation. Therefore, the nonparametric 
reference interval was calculated, and the median and 95% bootstrap CIs were reported. 
 
Independent sample t-tests were used to determine statistical difference between the BTM 
reference intervals for postmenopausal and premenopausal women. The Mann W hitney U-test was 
used to determine statistical difference between the PINP reference interval for postmenopausal 
and premenopausal women. 
 
Healthy postmenopausal women were used for further analysis to investigate other determinants of 
BTMs. Univariate analysis was performed to determine the effects of age, height, weight, body mass 
index (BMI), alcohol consumption and smoking on BTMs. 
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Results 
Subject characteristics 
The subject characteristics for the older and younger women in the OPUS study population are 
shown in Table 1. Overall, mean BMD T-scores at the spine and total hip were lower and mean levels 
of BTMs were higher in older women compared with the younger women. 
 
Effects of diseases and treatments on BTMs 
Multiple linear regression analysis was performed to assess the disease and treatments thought to 
influence bone turnover levels in older women, adjusting for age and menopause status Table 2. 
Levels of CTX, NTX, PINP and bone ALP were significantly higher by 5.7 W9.9% (P < 0.050) in subjects 
who were vitamin D deficient compared with those who had normal levels. Levels of NTX were 
significantly lower by 20.6% (P < 0.050) and osteocalcin higher by 27.4% (P < 0.010) in subjects who 
had stage 4 or 5 CKD compared with those with a normal eGFR. All BTMs were significantly higher in 
subjects who were osteoporotic at the spine by 10.9 W27.1% (P < 0.001) compared with those with a 
normal BMD T-score. All BTMs were significantly lower by 20.0 W36.3% (P < 0.001) in patients who 
were taking antiresorptive treatments or who were oestrogen replete compared with those who 
were not. Levels of NTX and bone ALP were significantly higher by 5.4 W6.4% (P < 0.050) in subjects 
who had a history of an adverse condition known to affect bone metabolism compared with those 
who did not. Overall, at least two BTMs were affected by each of the diseases or treatments that we 
investigated. Hence, it was therefore valid to use these as exclusion criteria for identifying a healthy 
set of subjects from whom we can determine BTM reference intervals for postmenopausal and 
premenopausal women. 
 
Healthy reference intervals 
There were 343 healthy postmenopausal women who had BMD T-score of > -2.5 at the lumbar spine 
and/or total hip, a 25(OH)D of >30 nmol/L, an eGFR of >30 mL/minute/1.73m², did not have a history 
of any adverse conditions that influence bone, did not take antiresorptive treatments within a year 
of starting the study and were not oestrogen replete or vitamin D insufficient. These were used to 
calculate the 95% reference intervals for each BTM (Table 3). The same inclusion criteria were 
applied to the younger women and 158 women were used to calculate the healthy premenopausal 
reference interval (Table 4). The postmenopausal reference intervals were significantly higher than 
those for premenopausal women for all BTMs, P<0.001 independent sample t-test (nonparametric 
Mann W hitney U-test for PINP). 
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The lower part of the premenopausal reference intervals have been previously proposed as a target 
for treatment. This range was 0.05  W 0.19 ng/ml for CTX, 15.0  W 38.1 nmol bone collagen 
equivalent (BCE) per mmol Cr for NTX, 4.2  W 30.1 ng/ml for PINP, 5.2  W 9.8 ng/ml for bone ALP and 
8.8  W 17.9 for osteocalcin. 
 
Determinants of BTMs in healthy postmenopausal women 
Univariate analyses were performed to study determinants thought to influence BTMs in healthy 
postmenopausal women. CTX, NTX, bone ALP and osteocalcin increased significantly with age 
(percentage increases per s.d. (6.6) were: CTX (11.7%, 95% CI: 8.1 W15.1, P<0.001), NTX (6.7%, 95% 
CI: 4.2 W9.1, P<0.001), bone ALP (4.7%, 95% CI: 3.0 W6.7, P<0.001) and osteocalcin (7.9%, 95%CI: 5.9 W
9.9, P<0.001)). Figure 1 shows the effect of age on CTX and NTX in all older and younger women 
used for this analysis. Osteocalcin decreased significantly by 25% (95% CI: 4.7 W40.8, P = 0.018) for 
each s.d. (4.1) increase in BMI. There was no significant association between any of the BTMs with 
weight and height. There was no significant difference in mean values of BTMs between women who 
drank alcohol and those who did not. Women who were current smokers had higher CTX (19.7%, 
95% CI: 9.6 W30.3, P<0.001), NTX (7.6%, 95% CI: 1.2 W14.8, P=0.022), PINP (7.6%, 95% CI: 0.2 W15.6, 
P=0.046) and bone ALP (6.9%, 95% CI: 2.1 W12.2, P=0.004) compared with nonsmokers. There was no 
significant difference in any of the BTMs between countries. 
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Discussion 
Reference intervals have been established for several clinically relevant bone resorption and 
formation markers in healthy postmenopausal women. Here we have used a large well characterised 
healthy population that will be useful to clinicians to help identify patients who may have secondary 
osteoporosis. In a previous study based on a cohort of Spanish postmenopausal women, reference 
intervals for CTX and PINP have been established using fasting serum [11], and these are comparable 
to the OPUS cohort. 
 
Several diseases and treatments influence BTMs in older women. Osteoporosis was associated with 
higher BTMs and antiresorptive treatments with lower BTMs. The decrease in BTMs following 
antiresorptive treatments has been well documented, reflecting the inhibition of bone remodelling 
[10, 28 W30]. There is a decrease in CTX and NTX within weeks after bisphosphonate treatment and is 
followed by a decrease in bone formation markers. 
 
BTMs are high in patients with vitamin D deficiency, mainly as a result of high PTH levels [16]. 
Osteocalcin levels are high in patients with CKD; however, there was a small number of patients in 
this group. This is consistent with previous work and may be related to decreased renal clearance 
and increased bone metabolism [31]. Median levels of PTH are 66.0 ng/ml in CKD group compared 
with 35.8 ng/ml in the healthy postmenopausal group, P<0.0001 (Mann W hitney test). Magnusson 
et al. [18] have also shown elevated levels of other BTMs cleared by renal filtration, that is, CTX and 
ICTP (crosslinked carboxyterminal telopeptide of type I collagen), in patients with chronic renal 
failure. 
 
Our findings demonstrate that there are several adverse conditions and treatments that affect BTMs 
in older women. These are therefore valid exclusion criteria and must be applied when establishing 
healthy postmenopausal reference intervals for BTMs. 
 
CTX has significant diurnal rhythm with a peak in the morning and a nadir in the afternoon. 
Circulating levels are influenced by food intake [32]. In nonfasting conditions, the peak is reached at 
night, followed by a significant decrease and nadir from 1100 to 1500 h. In our study, samples were 
collected at the same time of the day, in the afternoon between 1200 and 1500 h, thus reducing the 
day-to-day variation [33]. Establishing reference ranges based on the nonfasting state may be the 
best use of these data in a clinical practice. It is important to establish BTM reference intervals for 
healthy premenopausal women using newer, automated immunoassays and compare them with 
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other immunoassays. Levels of CTX in this study were lower than those established by De Papp et al. 
[34] and Glover et al. [6, 7] who used fasting serum samples and different assays. Levels of BTMs in 
postmenopausal women above the upper limit of the premenopausal reference interval are 
associated with an increase in the risk of fracture. Therefore, these reference intervals can also be 
used as a clinical tool to identify postmenopausal women who have high levels of bone turnover and 
increased risk of fracture [35]. Several lifestyle factors are significantly associated with bone 
turnover in postmenopausal women. This study has shown that postmenopausal women with a high 
BMI have lower levels of circulating osteocalcin. This may be related to increased hormone secretion 
from adipocytes that influence osteoblast and osteoclast activity [36], and is supported further by Di 
Carlo et al. [37] who demonstrated that leptin is significantly negatively correlated with osteocalcin 
in postmenopausal women receiving oestrogen Wprogestin therapy and also by Glover et al. [7] 
 
We have also demonstrated that postmenopausal women who were current smokers had higher 
levels of circulating CTX, NTX, PINP and bone ALP compared with nonsmokers. This finding is 
consistent with previous studies based on premenopausal women: Glover et al. [7] demonstrated 
higher levels of NTX and bone ALP compared with nonsmokers in women based in Sheffield. In 
another study, Glover et al. [6] also demonstrated higher levels of CTX and PINP compared with 
nonsmokers in women based in the United Kingdom, France, Belgium and the United States. These 
factors should therefore be considered when reporting BTM data in clinical studies. 
 
In conclusion, this study presents healthy postmenopausal reference intervals for clinically useful 
BTMs, using valid exclusion criteria. These differ from premenopausal reference intervals and, 
therefore, need to be determined separately. 
 
Our study had strengths and weaknesses. We used subjects from a large population-based study 
cohort (n=2419) in establishing the postmenopausal and premenopausal reference intervals for 
BTMs. We identified, assessed and excluded the important factors known to affect bone 
metabolism. This allowed us to identify a well-characterised population of a large sample size to 
reliably calculate the reference intervals. Assay consistency was maximised by using a central 
specialised laboratory with automated immunoassays for measuring the BTMs and thus minimising 
human error. 
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A limitation of this study was that serum was collected during a non-fasting state [38].  In addition, 
some of the data were obtained from a medical history questionnaire and some responses may have 
been inaccurate. 
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Table 1: Baseline characteristics of the older (55-79 years) and younger (30-39 years) women in the 
OPUS study 
Variable Older women ( N = 2419) Younger women ( N = 258) 
Age, years 67.1 (7.1) 35.5 (2.9) 
Height, cm 160.3 (6.3) 165.5 (6.8) 
Weight, kg 68.7 (12.3) 66.5 (13.2) 
BMI, kg/m2 26.7 (4.5) 24.3 (4.5) 
Lumbar spine BMD T-score -0.94 (1.5) 0.22 (1.1) 
Total hip BMD T-score -0.64 (1.2) 0.30 (1.0) 
Serum CTX, ng/mL 0.36 (0.27) 0.22 (0.14) 
Urine NTX nmol BCE/mmol Cr 51.1 (39.8) 41.68 (17.9) 
Serum PINP, ng/mL    42.5 (22.0) 35.7 (18.0) 
Serum Bone ALP, ng/mL 15.1 (6.4) 10.9 (4.2) 
Serum Osteocalcin ng/mL 23.4 (14.5) 19.1 (6.5) 
25 (OH) D nmol/L 21.4 (10.3) 24.4 (12.1) 
eGFR mL/minute/1.73m2 57.5 (13.4) 68.1 (12.1) 
Serum calcium 2.39 (0.15) 2.37 (0.13) 
 
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalent; BMD, bone mineral 
density; BMI, bone marrow index; CTX, C-terminal crosslinking telopeptides of type I collagen; eGFR, 
estimated glomerular filtration rate; N, number of subjects; NTX, N-terminal crosslinking 
telopeptides of type I collagen; 25(OH)D, 25 hydroxy vitamin D, PINP, procollagen type I N 
propeptide. 
Values are mean (s.d.). 
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Table 2: Percentage differences (95% confidence intervals) in the geometric means of BTMs from multiple linear regression coefficients: the effects of 
diseases and treatments on BTMs in all older women (55-79 years; n=2419) 
 
Bone turnover 
marker 
 No Disease 
or  
Treatment 
Vitamin D 
deficiency 
(n=428) 
CKD 
Stages 3 and 4 
(n =22) 
Osteoporosis 
Hip 
(n= 108) 
Osteoporosis 
Spine 
(n=317) 
Adverse 
Conditions 
(n = 732) 
Antiresorptive  
and  
Oestrogen Replete 
(n = 778) 
Serum CTX, 
ng/mL 
Geometric 
Mean 
0.30 0.33 0.35 0.37 0.39 0.32 0.19 
% Difference 
(95% CI) 
 9.9 
(2.1, 18.3)* 
15.1 
(-15.1, 55.6) 
21.6 
(5.7, 40.3)** 
27.1 
(16.7, 38.7)*** 
5.2 
(-1.1, 11.9) 
-36.3 
(-40.3, -32.1)*** 
Urine NTX, 
nmol BCE/ 
mmol Cr 
Geometric 
Mean 
46.4 49.1 36.9 57.3 57.8 49.3 33.1 
% Difference 
(95% CI) 
 5.7 
(0.1, 11.4)* 
-20.6 
(-35.7,-1.6)* 
23.3 
(10.9, 37.1)*** 
24.5 
(16.9, 32.7)*** 
6.2 
(1.4, 10.9)* 
-28.7 
(-31.9, -25.2)*** 
Serum PINP, 
ng/mL 
Geometric 
Mean 
38.9 42.0 40.4 41.7 47.5 39.7 27.7 
% Difference 
(95% CI) 
 8.1 
(1.9, 14.8)* 
4.0 
(-18.2, 32.4) 
7.2 
(-4.5, 20.2) 
22.2 
(14.0, 31.2)*** 
2.1 
(-3.2, 7.4) 
-27.7 
(-32.4, -24.7) 
Serum bone ALP, 
ng/mL 
Geometric 
Mean 
14.8 15.9 14.3 15.6 16.5 15.7 11.9 
% Difference 
(95% CI) 
 6.9 
(2.8, 11.4)*** 
-3.6 
(-18.0, 13.2) 
5.0 
(-2.7, 13.5) 
10.9 
(5.7, 16.1)*** 
5.4 
(1.9, 9.1)** 
-20.0 
(-22.0, -17.2)*** 
Serum 
Osteocalcin, 
ng/mL 
Geometric 
Mean 
22.4 23.3 28.6 26.5 25.1 22.1 16.5 
% Difference 
(95% CI) 
 3.8 
(-0.7, 8.4) 
27.4 
(6.9, 52.1)** 
18.0 
(8.4, 28.5)*** 
11.9 
(6.4, 17.8)*** 
-1.4 
(-4.9, 2.3) 
-26.4 
(-29.2, -23.6)*** 
 
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalent; BTM, bone turnover marker; CI, confidence interval; CKD, chronic kidney disease; 
CTX, C-terminal crosslinking telopeptides of type I collagen; NTX, N-terminal crosslinking telopeptides of type I collagen; PINP, procollagen type I N-
propeptide. Significance: *P<0.05, **P<0.01 and ***P<0.001. Geometric means are predictions from multiple linear regression adjusted for age and 
menopause status. 
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Table 3: Geometric mean (95% confidence interval) for the lower and upper limits of the reference intervals for BTMs for healthy postmenopausal women 
(n = 343) 
 
Bone turnover 
marker 
Geometric mean 
(95% reference 
interval) 
95% CI of the 
lower limit of the 
reference interval  
95% CI of upper 
limit of the 
reference interval 
Mean (SD) log10 
Serum CTX, ng/mL 0.31 (0.10  W 1.00) 0.09  W 0.11 0.90  W 1.11 -0.50 (0.256) 
Urine NTX nmol 
BCE/mmol Cr 
49.7 (21.2  W 116.4) 19.6  W 23.0 107.4  W 126.1 
1.7 (0.189) 
*Serum PINP, 
ng/mL  
41.3 ( 18.3  W 94.1) 12.8  W 20.3 79.4  W 112.1  
Serum Bone ALP, 
ng/mL 
14.1 (7.2  W 27.6) 6.8  W 7.7 26.0  W 29.4 1.2 (0.149) 
Serum Osteocalcin 
ng/mL 
24.5 (12.7  W 47.4) 11.9  W 13.5 44.6  W 50.4 1.4 (0.146) 
 
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalent; BTM, bone turnover marker; CI, confidence interval; CTX, C-terminal crosslinking 
telopeptides of type I collagen; NTX, N-terminal crosslinking telopeptides of type I collagen; PINP, procollagen type I N-propeptide. 
*The nonparametric reference interval was calculated. Median levels and 95% CIs are shown. 
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Table 4: Geometric mean (95% confidence intervals) for the lower and upper limits of the reference intervals for BTMs for healthy premenopausal women 
(n=158) 
 
Bone turnover 
marker 
Geometric mean 
(95% reference 
interval) 
95% CI of the 
lower limit of the 
reference interval  
95% CI of upper 
limit of the 
reference interval 
Mean (SD) log10 
Serum CTX, ng/mL 0.19 (0.05 - 0.63) 0.04  W 0.07 0.51  W 0.77 -0.73 (0.270) 
Urine NTX nmol 
BCE/mmol Cr 
38.1 (15.0  W 97.0) 12.8  W 17.5 82.8  W 113.7 
1.6 (0.207) 
*Serum PINP, 
ng/mL  
30.1 ( 4.2- 74.5) 3.0  W 13.8 60.8  W 79.4  
Serum Bone ALP, 
ng/mL 
9.8 (5.2  W 18.6) 4.6  W 5.7 16.7  W 20.7 1.0 (0.142) 
Serum Osteocalcin 
ng/mL 
17.9 (8.8  W 36.4) 7.9  W 9.9 32.3  W 40.9 1.3 (0.157) 
 
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalent; BTM, bone turnover marker; CI, confidence interval; CTX, C-terminal crosslinking 
telopeptides of type I collagen; NTX, N-terminal crosslinking telopeptides of type I collagen; PINP, procollagen type I N-propeptide. 
*The nonparametric reference interval was calculated. Median levels and 95% CIs are shown. 
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Figure 1: The effect of age on (a) CTX, (b) NTX, (c) PINP, (d) bone ALP and (e) osteocalcin in all older 
and younger women in the OPUS population. The solid black lines represent the upper limit, lower 
limit and geometric mean of the 95% reference intervals for healthy postmenopausal women. The 
dashed black lines represent the upper limit, lower limit and geometric mean of the 95% reference 
intervals for healthy premenopausal women. 
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